AKBA — Akebia Therapeutics, Inc.

Summary of AKBA Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $58.8 million, up from $37.4 million in Q3 2024.
• Net Product Revenues: $56.8 million, driven by:
  • Vafseo Sales: $14.3 million.
  • Auryxia Sales: $42.5 million, up from $35.6 million in Q3 2024.
• Cost of Goods Sold: Decreased to $9.4 million from $14.2 million due to the amortization of Auryxia product rights being fully expensed.
• R&D Expenses: Increased to $14.9 million from $8.5 million, reflecting higher clinical trial activities.
• SG&A Expenses: Increased to $29.1 million from $26.5 million, primarily due to marketing costs for Vafseo.
• Net Income: Approximately $540,000, a significant improvement from a net loss of $20 million in Q3 2024.
• Cash Position: $166.4 million in cash and equivalents.

2. Strategic Updates and Business Highlights

• Vafseo Launch: The product has generated more total prescriptions than any recent launch in dialysis within the first 41 weeks.
• Patient Access: Increased from 40,000 to nearly 70,000 patients due to partnerships with DaVita and other providers.
• Clinical Data: Positive data presented at the ASN meeting indicated Vafseo's potential to improve clinical outcomes for dialysis patients, which may support its adoption as a standard of care.
• Dosing Protocols: Engagement with the FDA to add a three-times-weekly (TIW) dosing regimen to the label, which is already being adopted by some providers.

3. Forward Guidance and Outlook

• Anticipated strong interest from physicians and increased prescribing access, particularly with the rollout of Vafseo in DaVita clinics, which now has access for over 200,000 patients.
• Expectation to start 2026 with access to nearly 7x the number of patients compared to the beginning of 2025.
• Continued efforts to address operational challenges and improve patient adherence are expected to enhance growth moving forward.

4. Challenges and Points of Concern

• Revenue Satisfaction: Management expressed dissatisfaction with the current revenue of $14.3 million from Vafseo, indicating operational issues are impacting growth.
• Adherence Issues: Lower-than-expected adherence rates at US Renal Care (USRC) are concerning, particularly with initial patient refills.
• Operational Hurdles: The complexity of the dialysis environment and the need for alignment with various providers' protocols are causing delays in patient onboarding.
• Generic Competition: Uncertainty regarding future Auryxia sales due to potential generic competition, although no generics have been approved yet.

5. Notable Q&A Insights

• Adherence Strategies: Management discussed the importance of educating anemia managers on titration strategies to improve adherence, as many are reverting to traditional ESA treatments.
• Feedback on Clinical Data: Positive physician feedback on the post-hoc analysis of Vafseo's impact on hospitalization outcomes was noted, suggesting strong support for the product's clinical benefits.
• Future Path for AKI Indication: Ongoing discussions with the FDA regarding the registrational path for AKB-9090 (acute kidney injury) are still in early stages, with no concrete plans yet.

Overall, while Akebia is experiencing strong revenue growth and positive clinical data, operational challenges and adherence issues remain significant hurdles that the company is actively working to address.